Skip to main content
MGNX logo

MGNX · Macrogenics Inc

Track MGNX — free
$4.22 +0.14 (+3.43%) At close · Aug 14
Market Cap
$268.81M
Shares
63.70M

Macrogenics Inc Earnings Call Transcripts

Every quarterly earnings call for Macrogenics Inc (MGNX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Earnings call
FY26 · Q1
2026-05-20
Macrogenics Inc Q1 FY2026 Earnings Call
Revenue
$20.77M
▲ 57.5% YoY
Diluted EPS
$-0.58
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Macrogenics Inc Q1 FY2025 Earnings Call
Revenue
$13.19M
▲ 44.9% YoY
Diluted EPS
$-0.65
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-20
Macrogenics Inc Q4 FY2024 Earnings Call
Revenue
$19.35M*
▲ 80.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-05
Macrogenics Inc Q3 FY2024 Earnings Call
Revenue
$110.71M
▲ 964.8% YoY
Diluted EPS
$0.90
▲ 221.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Macrogenics Inc Q2 FY2024 Earnings Call
Positive tone TAMARACK Phase II and vobra duo in mCRPC B7-H3 pipeline strategy (MGC026, enoblituzumab) R&D expense growth
Revenue
$10.80M
▼ 17.8% YoY
Diluted EPS
$-0.89
▼ 196.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Macrogenics Inc Q1 FY2024 Earnings Call
Positive tone TAMARACK Phase II study (vobramitamab duocarmazine in mCRPC) Dose selection between 2 mg/kg and 2.7 mg/kg Durability / response confirmation
Revenue
$9.10M
▼ 62.8% YoY
Diluted EPS
$-0.84
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-07
Macrogenics Inc Q4 FY2023 Earnings Call
Positive tone Vobramitamab duocarmazine (vobra duo) / TAMARACK Phase 2 ADC pipeline expansion Lorigerlimab / LORIKEET study
Revenue
$10.72M*
▼ 85.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Macrogenics Inc Q3 FY2023 Earnings Call
Revenue
$10.40M
▼ 75.1% YoY
Diluted EPS
$0.28
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Macrogenics Inc Q2 FY2023 Earnings Call
Revenue
$13.14M
▼ 49.5% YoY
Diluted EPS
$0.92
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Macrogenics Inc Q1 FY2023 Earnings Call
Revenue
$24.50M
▲ 120.7% YoY
Diluted EPS
$-0.61
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-15
Macrogenics Inc Q4 FY2022 Earnings Call
Revenue
$73.10M*
▲ 416.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Macrogenics Inc Q3 FY2022 Earnings Call
Revenue
$41.73M
▲ 166.5% YoY
Diluted EPS
$-0.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Macrogenics Inc Q2 FY2022 Earnings Call
Revenue
$26.01M
▼ 15.4% YoY
Diluted EPS
$-0.67
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Macrogenics Inc Q1 FY2022 Earnings Call
Revenue
$11.10M
▼ 34.2% YoY
Diluted EPS
$-1.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Macrogenics Inc Q4 FY2021 Earnings Call
Revenue
$14.15M*
▼ 73.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Macrogenics Inc Q3 FY2021 Earnings Call
Revenue
$15.66M
▼ 14.2% YoY
Diluted EPS
$-0.86
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-07-29
Macrogenics Inc Q2 FY2021 Earnings Call
Revenue
$30.76M
▲ 51.8% YoY
Diluted EPS
$-0.66
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-04-29
Macrogenics Inc Q1 FY2021 Earnings Call
Revenue
$16.88M
▲ 23.4% YoY
Diluted EPS
$-0.90
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Macrogenics Inc Q4 FY2020 Earnings Call
Revenue
$52.69M*
▲ 109.2% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Macrogenics Inc Q3 FY2020 Earnings Call
Revenue
$18.25M
▼ 2.6% YoY
Diluted EPS
$-0.66
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-31
Macrogenics Inc Q2 FY2020 Earnings Call
Revenue
$20.26M
▲ 91.2% YoY
Diluted EPS
$-0.94
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Macrogenics Inc Q1 FY2020 Earnings Call
Revenue
$13.68M
▲ 41.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–22 of 22 earnings calls
Key facts CIK 1125345 CUSIP 556099109 13F (30d) 126 filings 122 filers Visit website Investor relations